HC Wainwright Issues Negative Forecast for OKUR Earnings

OnKure Therapeutics (NASDAQ:OKUR) – HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of OnKure Therapeutics in a note issued to investors on Tuesday, March 18th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($1.41) per share for the quarter, down from their prior estimate of ($1.19). HC Wainwright has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for OnKure Therapeutics’ Q2 2025 earnings at ($1.43) EPS, Q3 2025 earnings at ($1.27) EPS, Q4 2025 earnings at ($1.15) EPS and FY2025 earnings at ($5.20) EPS.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings data on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.51).

OKUR has been the topic of a number of other reports. Oppenheimer cut their price objective on OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a report on Tuesday, March 11th. Leerink Partners began coverage on OnKure Therapeutics in a research report on Thursday, December 5th. They issued an “outperform” rating and a $33.00 target price for the company. Finally, Leerink Partnrs upgraded OnKure Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, OnKure Therapeutics has a consensus rating of “Buy” and an average target price of $32.33.

OnKure Therapeutics Stock Performance

Shares of OKUR opened at $5.00 on Thursday. OnKure Therapeutics has a fifty-two week low of $4.45 and a fifty-two week high of $20.00. The company has a fifty day moving average of $5.48. The firm has a market cap of $67.18 million, a price-to-earnings ratio of -0.41 and a beta of 0.28.

Institutional Trading of OnKure Therapeutics

Several institutional investors have recently added to or reduced their stakes in OKUR. Acorn Capital Advisors LLC acquired a new position in shares of OnKure Therapeutics in the 4th quarter worth approximately $12,381,000. Geode Capital Management LLC bought a new stake in shares of OnKure Therapeutics during the 4th quarter valued at about $659,000. Boothbay Fund Management LLC bought a new position in OnKure Therapeutics in the fourth quarter worth about $671,000. Samsara BioCapital LLC bought a new stake in shares of OnKure Therapeutics in the 4th quarter worth approximately $7,088,000. Finally, XTX Topco Ltd bought a new stake in OnKure Therapeutics in the fourth quarter valued at $160,000. 90.98% of the stock is owned by institutional investors and hedge funds.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.